Stay clear of coadministration of pazopanib with sturdy CYP3A4 inhibitors if possible; if will have to coadminister, lower pazopanib dose to four hundred mg/dayMinor (1)dasatinib and pazopanib both of those raise QTc interval. Slight/Importance Unidentified.Lower than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can result